Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in ...

Clinical trial data from Eli Lilly and Novo Nordisk suggest fewer than 10 ... 37% of people using a GLP-1 drug for either ...